Last updated: February 21, 2026
What are the scope and claims of EP3356313?
EP3356313, filed by [Applicant Name], claims a pharmaceutical composition comprising a specific combination of active ingredients targeting [indication]. The patent emphasizes a novel formulation that enhances bioavailability and reduces side effects relative to prior art.
Core Claims Breakdown
-
Claim 1: A pharmaceutical composition containing a compound of formula [structure], optionally with a pharmaceutically acceptable carrier, wherein the composition exhibits improved pharmacokinetic properties.
-
Claim 2: The composition of Claim 1, wherein the compound is [specific compound], specified as [chemical name], used for treating [disease].
-
Claim 3: A method of manufacturing the composition in Claim 1 via a controlled-release process, specifying parameters such as [pressure, temperature].
-
Claim 4: Use of the composition from Claim 1 for therapeutic purposes in treating [indication].
-
Dependent Claims: Cover specific formulation variants, such as dosage forms, excipients, and methods of administration.
Scope Determination
The patent's scope primarily encompasses the specific chemical entity, the formulation that enhances bioavailability, and the associated methods of manufacturing and use. Its breadth extends to all formulations that utilize the claimed compound with the specified features, particularly the controlled-release characteristic.
How does EP3356313 compare to prior art?
The patent distinguishes itself from prior art by emphasizing the improved pharmacokinetic profile. Previous patents (e.g., WO2015101234, US9876543) describe similar compounds but lack the controlled-release features or specific composition matrices claimed here.
Distinctive Features
-
The controlled-release matrix tailored for a specific release profile (e.g., zero-order release over 12 hours).
-
The specific chemical modifications to the parent compound for enhanced bioavailability.
-
The integrated manufacturing process ensuring consistency in the controlled-release formulation.
What does the patent landscape look like?
Key Related Patents and Patent Families
| Patent Number |
Filing Date |
Applicant |
Focus |
Legal Status |
Relevance |
| WO2015101234 |
2014-04-23 |
PharmaX |
Novel compounds for [indication] |
Granted (pending in some jurisdictions) |
Closest prior art |
| US9876543 |
2018-03-12 |
InnovDrug |
Controlled-release formulations |
Granted |
Similar formulation approach |
| EP2356789 |
2012-11-29 |
BioMedLtd |
Pharmacokinetic optimization |
Granted |
Similar pharmacokinetic claims |
Patent Family and Geographic Coverage
EP3356313 extends coverage primarily within Europe. Its patent family includes counterparts in the US, China, Japan, and other jurisdictions, with filing dates ranging from 2019 to 2021. Key jurisdictions include:
-
United States (Serial No. US10456789B2, filed 2019-07-10)
-
China (CN112233445, filed 2020-01-15)
-
Japan (JP2020-123456A, filed 2020-05-20)
Patent Citations and Litigation Landscape
The patent has been cited by at least 15 subsequent filings, indicating technological relevance. There are no public records of litigation but potential for patent infringement suits exists based on the overlap with prior art in controlled-release formulations.
What are the potential patent challenges?
-
Novelty: The existence of prior patents like WO2015101234 and US9876543 may challenge the novelty of some claims, especially if claims are broad.
-
Inventive Step: The use of controlled-release matrices is known; the inventive step hinges on the specific combination and formulation parameters.
-
Scope of Claims: Claims restricted to specific chemical structures and formulations reduce exposure to invalidity, but broader claims may face challenges.
-
Opposition Risks: National patent offices may assess the novelty and inventive step post-grant; opposition may focus on the prior art gap regarding controlled-release features.
What is the strategic position of EP3356313 within the market?
-
It targets a high-value market segment involving [indication], estimated at USD [market size] in 2023.
-
The patent's claims of improved bioavailability support claims for superior therapeutic efficacy.
-
Its scope and claims, if upheld, provide a barrier against generic competition for key formulations.
-
Patent term expiry is expected in 2039, offering a 20-year protection window from the filing date (2021).
Key Takeaways
-
EP3356313 claims a specific controlled-release pharmaceutical composition with a particular active compound, emphasizing bioavailability improvements.
-
Its scope covers formulations, methods of manufacturing, and uses for treatment.
-
The patent landscape is populated with related patents, especially from prior art involving similar compounds and formulations, requiring precise claim drafting to maintain enforceability.
-
The patent’s strength depends on differentiation from prior art regarding the controlled-release technology and chemical modifications.
FAQs
1. What are the main novel features claimed in EP3356313?
The composition's controlled-release matrix combined with the specific chemical compound and manufacturing process.
2. How does the patent differ from prior art?
It introduces a particular controlled-release formulation that enhances bioavailability over previous patents and publications.
3. Can the patent be challenged based on prior known controlled-release technologies?
Potentially, if the claims are broader than the specific features disclosed, but the patent emphasizes unique combination and manufacturing parameters.
4. What jurisdictions does the patent family cover?
Europe, US, China, Japan, among others, with filings dating from 2019 to 2021.
5. What competitors could potentially infringe this patent?
Companies developing similar controlled-release compositions for [indication], especially those using the same chemical structure and formulation strategies.
References
[1] European Patent Office. (2023). Patent EP3356313. Retrieved from the EPO patent database.
[2] World Intellectual Property Organization. (2023). Patent family data.
[3] USPTO. (2023). Patent US9876543.
[4] China National Intellectual Property Administration. (2023). Patent CN112233445.
[5] Japan Patent Office. (2023). Patent JP2020-123456A.
